Maria A Donahue, Julianne D Brooks, John Hsu, Mary Price, Deborah Blacker, Lee H Schwamm, Joseph P Newhouse, M Brandon Westover, Sebastien Haneuse, Lidia M V R Moura
{"title":"Differences in patterns of outpatient epilepsy-specific medication initiation after acute ischemic stroke in the Medicare population.","authors":"Maria A Donahue, Julianne D Brooks, John Hsu, Mary Price, Deborah Blacker, Lee H Schwamm, Joseph P Newhouse, M Brandon Westover, Sebastien Haneuse, Lidia M V R Moura","doi":"10.1111/epi.18396","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Acute ischemic stroke (AIS) is a leading hospitalization cause and significantly contributes to seizures among older adults. We examined outpatient epilepsy-specific medication (ESM) initiation patterns after AIS discharge in adults 65 years and older, trends over time (by stratifying the analysis from 2013 to 2021), and racial/ethnic differences.</p><p><strong>Methods: </strong>We analyzed nationwide administrative claims data for a 20% sample of US Medicare beneficiaries (enrolled in Traditional Medicare Parts A, B, and D for at least 12 months before admission) aged ≥65 years and hospitalized for AIS between 2013 and 2021. We estimated the cumulative incidence of ESM initiation within 90 days after AIS discharge, with mortality as a competing risk and censoring person time if individuals experienced an inpatient readmission. We described drug type and stratified our analysis by race, ethnicity, US geographic region, hospital region, and year of discharge.</p><p><strong>Results: </strong>Of 128 174 community-dwelling beneficiaries after AIS discharge, 2435 (1.9%, 95% confidence interval [CI] = 1.8%-2.0%) initiated ESM within the 90-day follow-up period and levetiracetam was the most common medication across all years (81%). Mean age was 79 years (range = 65-110), 56% were female, 81% were non-Hispanic White, 10% were Black/African American, 5% were Hispanic, and 3% were Asian. The cumulative incidence of ESM initiation at 90 days in the overall sample was 1.4% (95% CI = 1.3%-1.4%); it was 1.8% (95% CI = 1.6%-2.1%) for Black/African American, 1.9% (95% CI = 1.6%-2.3%) for Hispanic, and 1.2% (95% CI = 1.2%-1.3%) for non-Hispanic White beneficiaries. The 90-day cumulative incidence also varied by US Census division, from 1.0% (95% CI = .8-1.3; West North Central) to 1.5% (95% CI = 1.3%-1.8%; East South Central). We observed an increase in ESM 90-day initiation over time, from 1.2% (95% CI = 1.0%-1.5%) in 2013 to 1.7% (95% CI = 1.5%-1.9%) in 2021. ESM initiation was 1.6% (95% CI = 1.4%-1.8%) in the 65-70-year age group and decreased in older age groups.</p><p><strong>Significance: </strong>Black/African American and Hispanic beneficiaries had a higher 90-day incidence of post-AIS ESM initiation than non-Hispanic Whites. ESM initiation decreased in older age groups.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/epi.18396","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Acute ischemic stroke (AIS) is a leading hospitalization cause and significantly contributes to seizures among older adults. We examined outpatient epilepsy-specific medication (ESM) initiation patterns after AIS discharge in adults 65 years and older, trends over time (by stratifying the analysis from 2013 to 2021), and racial/ethnic differences.
Methods: We analyzed nationwide administrative claims data for a 20% sample of US Medicare beneficiaries (enrolled in Traditional Medicare Parts A, B, and D for at least 12 months before admission) aged ≥65 years and hospitalized for AIS between 2013 and 2021. We estimated the cumulative incidence of ESM initiation within 90 days after AIS discharge, with mortality as a competing risk and censoring person time if individuals experienced an inpatient readmission. We described drug type and stratified our analysis by race, ethnicity, US geographic region, hospital region, and year of discharge.
Results: Of 128 174 community-dwelling beneficiaries after AIS discharge, 2435 (1.9%, 95% confidence interval [CI] = 1.8%-2.0%) initiated ESM within the 90-day follow-up period and levetiracetam was the most common medication across all years (81%). Mean age was 79 years (range = 65-110), 56% were female, 81% were non-Hispanic White, 10% were Black/African American, 5% were Hispanic, and 3% were Asian. The cumulative incidence of ESM initiation at 90 days in the overall sample was 1.4% (95% CI = 1.3%-1.4%); it was 1.8% (95% CI = 1.6%-2.1%) for Black/African American, 1.9% (95% CI = 1.6%-2.3%) for Hispanic, and 1.2% (95% CI = 1.2%-1.3%) for non-Hispanic White beneficiaries. The 90-day cumulative incidence also varied by US Census division, from 1.0% (95% CI = .8-1.3; West North Central) to 1.5% (95% CI = 1.3%-1.8%; East South Central). We observed an increase in ESM 90-day initiation over time, from 1.2% (95% CI = 1.0%-1.5%) in 2013 to 1.7% (95% CI = 1.5%-1.9%) in 2021. ESM initiation was 1.6% (95% CI = 1.4%-1.8%) in the 65-70-year age group and decreased in older age groups.
Significance: Black/African American and Hispanic beneficiaries had a higher 90-day incidence of post-AIS ESM initiation than non-Hispanic Whites. ESM initiation decreased in older age groups.
目的:急性缺血性脑卒中(AIS)是导致老年人癫痫发作的主要住院原因。我们检查了65岁及以上成人在AIS出院后的门诊癫痫特异性药物(ESM)启动模式,随时间的趋势(通过2013年至2021年的分层分析),以及种族/民族差异。方法:我们分析了2013年至2021年期间因AIS住院的年龄≥65岁的20%的美国医疗保险受益人(入院前至少12个月参加传统医疗保险a、B和D部分)的全国行政索赔数据。我们估计了AIS出院后90天内ESM启动的累积发生率,死亡率是一个竞争风险,如果个体经历了住院再入院,则审查了人的时间。我们描述了药物类型,并按种族、民族、美国地理区域、医院区域和出院年份对分析进行了分层。结果:在128 174名AIS出院后的社区居住受益人中,2435人(1.9%,95%可信区间[CI] = 1.8%-2.0%)在90天的随访期内开始了ESM治疗,左乙拉西坦是所有年中最常用的药物(81%)。平均年龄79岁(65-110岁),56%为女性,81%为非西班牙裔白人,10%为黑人/非洲裔美国人,5%为西班牙裔,3%为亚洲人。在整个样本中,90天ESM启动的累积发生率为1.4% (95% CI = 1.3%-1.4%);黑人/非裔美国人为1.8% (95% CI = 1.6%-2.1%),西班牙裔为1.9% (95% CI = 1.6%-2.3%),非西班牙裔白人为1.2% (95% CI = 1.2%-1.3%)。90天累积发病率也因美国人口普查部门而异,从1.0% (95% CI = 0.8 -1.3;西、北、中)至1.5% (95% CI = 1.3%-1.8%;东南中部)。我们观察到,随着时间的推移,90天ESM起始率从2013年的1.2% (95% CI = 1.0%-1.5%)增加到2021年的1.7% (95% CI = 1.5%-1.9%)。在65-70岁年龄组中,ESM起始率为1.6% (95% CI = 1.4%-1.8%),在老年组中下降。意义:黑人/非裔美国人和西班牙裔受益人在ais后90天的ESM发生率高于非西班牙裔白人。ESM起始率在老年组中下降。
期刊介绍:
Epilepsia is the leading, authoritative source for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.